Literature DB >> 10633085

Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1.

S Miotti1, M Bagnoli, A Tomassetti, M I Colnaghi, S Canevari.   

Abstract

Using as a model the ovary carcinoma cell line IGROV1, we analyzed the partitioning of the glycosyl-phosphatidylinositol-anchored folate receptor into lipid rafts based on its relative detergent insolubility, with a focus on physically and functionally associated signaling molecules. A variable amount (40-60%) of folate receptor was found in low-density Triton X-100 insoluble complexes together with subunits of heterotrimeric G-proteins and the src-family non-receptor tyrosine kinases p53-56 lyn. In the same fraction the structural component of caveolae, caveolin, was not detected at the protein level, although the corresponding mRNA was detected in trace amounts. Comodulation of folate receptor and signalling molecules was observed in the detergent-insoluble complexes during cell proliferation or induced by phosphatidylinositol-specific phospholipase C treatment or by interaction with anti-folate receptor monoclonal antibodies. Moreover, complexes of folate receptor, lyn and the G(&agr;)(i-3) subunit were immunoprecipitated using either anti-folate receptor or anti-lyn antibodies. In vitro kinase assay of the immunoprecipitates revealed stimulation of phosphorylation of common and specific proteins. In particular, the p53 form of lyn appeared to be enriched and phosphorylated in the anti-folate receptor MOv19 monoclonal antibody immunoprecipitate, whereas a 40 kDa band common to anti-folate receptor and anti-lyn immunoprecipitates was the phosphorylated form of the G(&agr;)(i-3) subunit. These findings point to the functional interaction between folate receptor and associated signaling molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10633085     DOI: 10.1242/jcs.113.2.349

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  23 in total

1.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

2.  Role of farletuzumab in epithelial ovarian carcinoma.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Sperm-oocyte contact induces outside-in signaling via PYK2 activation.

Authors:  Huizhen Wang; Jinping Luo; Carol Carlton; Lynda K McGinnis; William H Kinsey
Journal:  Dev Biol       Date:  2017-05-17       Impact factor: 3.582

4.  Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

Authors:  Yu-Li Chen; Ming-Cheng Chang; Chia-Yen Huang; Ying-Cheng Chiang; Han-Wei Lin; Chi-An Chen; Chang-Yao Hsieh; Wen-Fang Cheng
Journal:  Mol Oncol       Date:  2011-12-20       Impact factor: 6.603

5.  Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases.

Authors:  Silvia Miotti; Antonella Tomassetti; Ileana Facetti; Elena Sanna; Valeria Berno; Silvana Canevari
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 6.  Emerging roles for folate receptor FOLR1 in signaling and cancer.

Authors:  Fathima Zahra Nawaz; Edward T Kipreos
Journal:  Trends Endocrinol Metab       Date:  2022-01-31       Impact factor: 12.015

7.  Novel folate binding protein-1 interactions in embryonic orofacial tissue.

Authors:  M Michele Pisano; Vasker Bhattacherjee; Leeyean Wong; Richard H Finnell; Robert M Greene
Journal:  Life Sci       Date:  2010-01-05       Impact factor: 5.037

8.  Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Authors:  Wolfgang Ebel; Eric L Routhier; Brian Foley; Sara Jacob; Jennifer M McDonough; Rina K Patel; Howard A Turchin; Qimin Chao; J Bradford Kline; Lloyd J Old; Martin D Phillips; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso
Journal:  Cancer Immun       Date:  2007-03-09

9.  Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Authors:  Anthony Cheung; James Opzoomer; Kristina M Ilieva; Patrycja Gazinska; Ricarda M Hoffmann; Hasan Mirza; Rebecca Marlow; Erika Francesch-Domenech; Matthew Fittall; Diana Dominguez Rodriguez; Angela Clifford; Luned Badder; Nirmesh Patel; Silvia Mele; Giulia Pellizzari; Heather J Bax; Silvia Crescioli; Gyula Petranyi; Daniel Larcombe-Young; Debra H Josephs; Silvana Canevari; Mariangela Figini; Sarah Pinder; Frank O Nestle; Cheryl Gillett; James F Spicer; Anita Grigoriadis; Andrew N J Tutt; Sophia N Karagiannis
Journal:  Clin Cancer Res       Date:  2018-08-01       Impact factor: 12.531

10.  Early detection biomarkers for ovarian cancer.

Authors:  Sreeja Sarojini; Ayala Tamir; Heejin Lim; Shihong Li; Shifang Zhang; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Oncol       Date:  2012-12-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.